Cargando…
Expression Analysis of α5 Integrin Subunit Reveals Its Upregulation as a Negative Prognostic Biomarker for Glioblastoma
Integrin α5β1 was suggested to be involved in glioblastoma (GBM) aggressiveness and treatment resistance through preclinical studies and genomic analysis in patients. However, further protein expression data are still required to confirm this hypothesis. In the present study, we investigated by immu...
Autores principales: | Etienne-Selloum, Nelly, Prades, Julien, Bello-Roufai, Diana, Boone, Mathieu, Sevestre, Henri, Trudel, Stéphanie, Caillet, Pascal, Coutte, Alexandre, Desenclos, Christine, Constans, Jean-Marc, Martin, Sophie, Choulier, Laurence, Chauffert, Bruno, Dontenwill, Monique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465081/ https://www.ncbi.nlm.nih.gov/pubmed/34577582 http://dx.doi.org/10.3390/ph14090882 |
Ejemplares similares
-
A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials
por: Cruz Da Silva, Elisabete, et al.
Publicado: (2021) -
Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment
por: Darmon, Ilan, et al.
Publicado: (2017) -
Expression/activation of α5β1 integrin is linked to the β-catenin signaling pathway to drive migration in glioma cells
por: Renner, Guillaume, et al.
Publicado: (2016) -
Combining genomic analyses with tumour-derived slice cultures for the characterization of an EGFR-activating kinase mutation in a case of glioblastoma
por: Loriguet, Lea, et al.
Publicado: (2018) -
Role of Integrins in Resistance to Therapies Targeting Growth Factor Receptors in Cancer
por: Cruz da Silva, Elisabete, et al.
Publicado: (2019)